STSI hit 5.00 intraday in early July. You will see $1.50 in March before you see $3.50. The fundamentals don't support $3.50 right now but a positive annual report will help get it off the bottom which is coming as I predicted here earlier (sorry post was deleted but some will recall it). $1.50-$1.80 trading range until the annual comes out, retest of the November low. The balance sheet is in decent shape and the goal of profitability in 2013 is achievable. Time will tell.
It's a nice product and a spec stock but you have to try to ignore the hoo-hah that gets posted, like some news item will take us to the moon, Alice! No, it won't. Because it never has. This is an otc nutraceutical and as such is looked at more skeptically than a drug in FDA trials and is unlikely to explode the way drug trial stocks sometimes do. There is no huge overhang of institutional ownership waiting with bated breath for a drug trial news release, so they can subsequently send the stock "to da Moon" (or to the gutter). I do think that growing sales will eventually grow the share price.
Lawsuit news used to move this stock at times, and there were a couple items from Altucher a few years ago on anatabine that caused a run or two, but he is an author with a lot of followers who dabble in spec stocks. I guess the Fuerstein hit pieces might have had some impact but they frankly were pretty lame and would only impact dummies, not most investors with a brain. Then there are the paid bashers who hang around. God help the dummies that pay them. Again, no investor with a brain would bother with that fluff.
This company has a lot of history to overcome - failed promises, shady pasts, poor performance. That said, the product has a lot of promise and sales are increasing strongly. So it's worth holding at this point, imho.
I ought to add that those wild ups are usually followed by a down. Steady sales/earning growth is the scenario that has legs imo.
AI
Market Data 
Markets 
